Dotamtate Pb-212

Neuroendocrine Tumors Market to grow at 5.1% CAGR (2020-2034) driven by upcoming therapies, rising incident cases, and increased research. Key players include Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size in 6MM.

Global peptide cancer drug market to exceed US$ 18 billion by 2030, with over 30 approved drugs and 230 in clinical trials. Peptides offer targeted, less toxic cancer treatments, with major players like Novartis and emerging firms driving innovation.

Global peptide cancer drug market expected to exceed $18 billion, with over 30 approved drugs and 230 in clinical trials. Peptides offer targeted, less toxic cancer treatments, combining biologics' specificity with small molecules' cost-effectiveness. Major players include Novartis and Roche, with US leading R&D, supported by FDA's expedited approvals.

Orano Med's Advanced Thorium Extraction Facility will supply lead-212 for global cancer treatments, including AlphaMedix in Phase II trials. The 7,000-square-meter plant aims to ensure large-scale production and distribution, set to open in 2027.

Sanofi reports 15.7% Q3 sales growth, driven by vaccine sales and strong business performance, raising 2024 EPS guidance. Dupixent sales up 23.8%, with full-year target confirmed at €13 billion. Pharma launches grew 67.1%, led by ALTUVIIIO, Nexviazyme, and Rezurock. Vaccines sales increased 25.5%, boosted by flu sales and Beyfortus. Opella sales rose 7.9%, supported by Qunol acquisition. R&D expenses grew 12.7%, while SG&A expenses grew 6.4%. Business EPS at €2.86, up 12.2% reported and 17.6% at CER. Four regulatory approvals and four positive phase 3 data readouts achieved. Negotiations underway to transfer a controlling stake of Opella to CD&R. 2024 business EPS guidance upgraded to low single-digit growth at CER.

Sanofi and Orano Med collaborate to develop next-gen radioligand medicines for rare cancers, leveraging Orano Med's expertise in targeted alpha therapies and Sanofi's biopharma capabilities.

Sanofi partners with RadioMedix and Orano Med for late-stage development of AlphaMedix (212Pb-DOTAMTATE), a targeted alpha therapy for somatostatin-receptor-expressing neuroendocrine tumours. Orano Med will manufacture, Sanofi will commercialize, and both will receive upfront and milestone payments. AlphaMedix received FDA Breakthrough Therapy Designation based on Phase 1 and 2 clinical study results.

Sanofi, RadioMedix, and Orano Med collaborate on AlphaMedix, a targeted alpha therapy for neuroendocrine tumors, granted Breakthrough Therapy Designation by the FDA. Sanofi to commercialize, Orano Med to manufacture, with an upfront payment of €100 million and potential milestones up to €220 million.

Sanofi signs exclusive licensing agreement with RadioMedix and Orano Med to advance AlphaMedix, a radioligand therapy for rare cancers, with a €100m upfront payment and potential €220m in sales-based milestones.